14-day Premium Trial Subscription Sign Up For FreeGet Free
Nasdaq - Total Crash or Bounce-Up? Click To Watch.

$9.36 (2.74%)

Volume: 404.475k

Closed: Sep 30, 2022

Hollow Logo Score: -1.864

Cara Therapeutics Stock Forecast

$9.36 (2.74%)

Volume: 404.475k

Closed: Sep 30, 2022

Score Hollow Logo -1.864

Cara Therapeutics Company Profile

4 Stamford Plaza, 9th Floor 107 Elm Street

Stamford CT 06902

203 406 3700

www.caratherapeutics.com

Industry: Biotechnology

Sector: Healthcare

Cara Therapeutics

Description

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Hot Stocks To Watch:

About Cara Therapeutics

Cara Therapeutics Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of mod... CARA Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT